Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorSanegre, Sabina
dc.contributor.authorEritja, Núria
dc.contributor.authorde Andrea, Carlos
dc.contributor.authorDiaz-Martin, Juan
dc.contributor.authorDiaz-Lagares, Ángel
dc.contributor.authorJácome, María Amalia
dc.contributor.authorRamon y Cajal Agüeras, Santiago
dc.date.accessioned2022-03-24T14:03:20Z
dc.date.available2022-03-24T14:03:20Z
dc.date.issued2021-06
dc.identifier.citationSanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares Á, Jácome MA, et al. Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. Front Cell Dev Biol. 2021 Jun;9:670185.
dc.identifier.issn2296-634X
dc.identifier.urihttp://hdl.handle.net/11351/7262
dc.descriptionEpigenetic profiles; Extracellular matrix; Immune cells
dc.description.abstractThe invasive tumor front (the tumor–host interface) is vitally important in malignant cell progression and metastasis. Tumor cell interactions with resident and infiltrating host cells and with the surrounding extracellular matrix and secreted factors ultimately determine the fate of the tumor. Herein we focus on the invasive tumor front, making an in-depth characterization of reticular fiber scaffolding, infiltrating immune cells, gene expression, and epigenetic profiles of classified aggressive primary uterine adenocarcinomas (24 patients) and leiomyosarcomas (11 patients). Sections of formalin-fixed samples before and after microdissection were scanned and studied. Reticular fiber architecture and immune cell infiltration were analyzed by automatized algorithms in colocalized regions of interest. Despite morphometric resemblance between reticular fibers and high presence of macrophages, we found some variance in other immune cell populations and distinctive gene expression and cell adhesion-related methylation signatures. Although no evident overall differences in immune response were detected at the gene expression and methylation level, impaired antimicrobial humoral response might be involved in uterine leiomyosarcoma spread. Similarities found at the invasive tumor front of uterine adenocarcinomas and leiomyosarcomas could facilitate the use of common biomarkers and therapies. Furthermore, molecular and architectural characterization of the invasive front of uterine malignancies may provide additional prognostic information beyond established prognostic factors.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Cell and Developmental Biology;9
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectÚter - Tumors
dc.subjectMúsculs - Càncer
dc.subjectMarcadors tumorals
dc.subject.meshLeiomyosarcoma
dc.subject.meshUterine Neoplasms
dc.subject.meshBiomarkers, Tumor
dc.titleCharacterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fcell.2021.670185
dc.subject.decsleiomiosarcoma
dc.subject.decsneoplasias uterinas
dc.subject.decsmarcadores tumorales
dc.relation.publishversionhttps://doi.org/10.3389/fcell.2021.670185
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Sanegre S] Cancer CIBER (CIBERONC), Madrid, Spain. Department of Pathology, School of Medical, University of Valencia-INCLIVA, Valencia, Spain. [Eritja N] Cancer CIBER (CIBERONC), Madrid, Spain. Institut de Recerca Biomèdica de LLeida (IRBLLEIDA), Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Department of Pathology, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, University of Lleida - University of Barcelona, Barcelona, Spain. [de Andrea C] Cancer CIBER (CIBERONC), Madrid, Spain. Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain. [Diaz-Martin J] Cancer CIBER (CIBERONC), Madrid, Spain. Institute of Biomedicine of Sevilla, Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Seville, Spain. [Diaz-Lagares Á] Cancer CIBER (CIBERONC), Madrid, Spain. Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain. [Jácome MA] Department of Mathematics, MODES Group, CITIC, Faculty of Science, Universidade da Coruña, A Coruña, Spain. [Ramon Y Cajal S] Cancer CIBER (CIBERONC), Madrid, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid34150764
dc.identifier.wos000662202000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record